A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).-MedSci.cn

A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).

Janjigian, YY; Viglianti, N; Liu, F; Mendoza-Naranjo, A; Croydon, L

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (3):

科室
- - 订阅+
  - 更多科室
工具
服务